{"PubmedArticle": [{"MedlineCitation": {"InvestigatorList": [], "SpaceFlightMission": [], "CitationSubset": ["IM"], "KeywordList": [], "GeneralNote": [], "OtherAbstract": [], "OtherID": [], "PMID": "8541815", "DateCompleted": {"Year": "1996", "Month": "02", "Day": "13"}, "DateRevised": {"Year": "2016", "Month": "10", "Day": "20"}, "Article": {"Language": ["eng"], "ELocationID": [], "ArticleDate": [], "Journal": {"ISSN": "1122-0643", "JournalIssue": {"Volume": "50", "Issue": "5", "PubDate": {"Year": "1995", "Month": "Oct"}}, "Title": "Monaldi archives for chest disease = Archivio Monaldi per le malattie del torace", "ISOAbbreviation": "Monaldi Arch Chest Dis"}, "ArticleTitle": "Intraluminal inflammation in the airways of patients with chronic bronchitis after treatment with Ambroxol.", "Pagination": {"StartPage": "346", "EndPage": "351", "MedlinePgn": "346-51"}, "Abstract": {"AbstractText": ["Ambroxol is a mucus-modifying drug with a known ability to stimulate surfactant secretion and inhibit, in vitro, the production of proinflammatory cytokines, neutrophil chemotaxis, and Na+ absorption by the airway epithelium. In dogs inhaling ozone, bronchial hyperreactivity can be inhibited by aerosolized Ambroxol. To verify the possibility of producing anti-inflammatory effects in a clinically relevant condition, 20 patients with chronic bronchitis, randomly divided into two balanced matched groups, were submitted to a 14 day trial with Ambroxol, 150 mg.day-1, or placebo, according to a double-blind design. A bronchoalveolar lavage (BAL) was performed the day before starting treatment (T0) and at the 14th day (T14). The analysis of the cellular and soluble (total proteins, albumin, immunoglobulin G and A (IgG and IgA)) BAL components demonstrated no clear modifications. In particular, neutrophil values from the bronchial aliquot showed a large dispersion, with no significant differences (Ambroxol: T0 = 13.7 +/- 5.2%, T14 = 14.0 +/- 6.8%; placebo: T0 = 3.6 +/- 1.1%, T14 = 5.5 +/- 2.2%). We found a nonsignificant increase of phospholipids in BAL supernatants from Ambroxol-treated patients (2.5 +/- 1.9 vs 3.0 +/- 1.9 micrograms.mg-1 of protein); whilst in the placebo group data before and after treatment were superimposable (2.2 +/- 1.5 vs 2.3 +/- 1.9 micrograms.mg-1 of protein). In conclusion, we have failed to demonstrate that conventional treatment with oral Ambroxol can modify surfactant and BAL cell populations in the airways of patients with chronic bronchitis."]}, "AuthorList": [{"AffiliationInfo": [{"Identifier": [], "Affiliation": "Clinica del Lavoro Foundation, IRCCS, Division of Pulmonary Disease, Medical Center of Rehabilitation, Veruno, Italy."}], "Identifier": [], "LastName": "Lusuardi", "ForeName": "M", "Initials": "M"}, {"AffiliationInfo": [], "Identifier": [], "LastName": "Capelli", "ForeName": "A", "Initials": "A"}, {"AffiliationInfo": [], "Identifier": [], "LastName": "Salmona", "ForeName": "M", "Initials": "M"}, {"AffiliationInfo": [], "Identifier": [], "LastName": "Tacconi", "ForeName": "M T", "Initials": "MT"}, {"AffiliationInfo": [], "Identifier": [], "LastName": "Cerutti", "ForeName": "C G", "Initials": "CG"}, {"AffiliationInfo": [], "Identifier": [], "LastName": "Donner", "ForeName": "C F", "Initials": "CF"}], "PublicationTypeList": ["Clinical Trial", "Journal Article", "Randomized Controlled Trial", "Research Support, Non-U.S. Gov't"]}, "MedlineJournalInfo": {"Country": "Italy", "MedlineTA": "Monaldi Arch Chest Dis", "NlmUniqueID": "9307314", "ISSNLinking": "1122-0643"}, "ChemicalList": [{"RegistryNumber": "0", "NameOfSubstance": "Expectorants"}, {"RegistryNumber": "200168S0CL", "NameOfSubstance": "Ambroxol"}], "MeshHeadingList": [{"QualifierName": ["therapeutic use"], "DescriptorName": "Ambroxol"}, {"QualifierName": ["metabolism", "pathology"], "DescriptorName": "Bronchi"}, {"QualifierName": ["drug therapy", "metabolism", "pathology"], "DescriptorName": "Bronchitis"}, {"QualifierName": ["chemistry", "cytology"], "DescriptorName": "Bronchoalveolar Lavage Fluid"}, {"QualifierName": [], "DescriptorName": "Chronic Disease"}, {"QualifierName": [], "DescriptorName": "Double-Blind Method"}, {"QualifierName": ["therapeutic use"], "DescriptorName": "Expectorants"}, {"QualifierName": [], "DescriptorName": "Female"}, {"QualifierName": [], "DescriptorName": "Humans"}, {"QualifierName": ["pathology"], "DescriptorName": "Inflammation"}, {"QualifierName": [], "DescriptorName": "Male"}, {"QualifierName": [], "DescriptorName": "Middle Aged"}]}, "PubmedData": {"ReferenceList": [], "History": [{"Year": "1995", "Month": "10", "Day": "1"}, {"Year": "1995", "Month": "10", "Day": "1", "Hour": "0", "Minute": "1"}, {"Year": "1995", "Month": "10", "Day": "1", "Hour": "0", "Minute": "0"}], "PublicationStatus": "ppublish", "ArticleIdList": ["8541815"]}}], "PubmedBookArticle": []}